It's a flop: Gilead's top late-stage drug selonsertib flunked its first Phase III NASH trial

Gilead’s high profile STELLAR-4 study of its top late-stage NASH drug selonsertib has hit the finish line, and it’s starting out Phase III results with a big-time failure.